GlobeNewswire: News from New Jersey Contains the last 10 of 38817 releaseshttp://www.globenewswire.com/External?Length=42024-03-29T13:30:03ZGlobeNewswirehttp://www.globenewswire.com/External?Length=4newsdesk@globenewswire.com (NewsDesk)https://www.globenewswire.com/news-release/2024/03/28/2854592/0/en/South-Jersey-Industries-Inc-Announces-Results-of-Final-Remarketing-of-Series-B-1-65-Remarketable-Junior-Subordinated-Notes-due-2029.html?f=22&fvtc=8&fvtv=New%20JerseySouth Jersey Industries, Inc. Announces Results of Final Remarketing of Series B 1.65% Remarketable Junior Subordinated Notes due 2029 2024-03-28T22:52:03Z<![CDATA[Folsom, NJ, March 28, 2024 (GLOBE NEWSWIRE) -- FOR IMMEDIATE RELEASE]]>https://www.globenewswire.com/news-release/2024/03/28/2854435/0/en/SCYNEXIS-Reports-Full-Year-2023-Financial-Results-and-Provides-Corporate-Update.html?f=22&fvtc=8&fvtv=New%20JerseySCYNEXIS Reports Full Year 2023 Financial Results and Provides Corporate Update2024-03-28T20:01:00Z<![CDATA[JERSEY CITY, N.J., March 28, 2024 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant infections, today reported financial results for the year ended December 31, 2023.]]>https://www.globenewswire.com/news-release/2024/03/28/2854245/0/en/Milestone-Scientific-Schedules-2023-Year-End-Financial-Results-and-Business-Update-Conference-Call.html?f=22&fvtc=8&fvtv=New%20JerseyMilestone Scientific Schedules 2023 Year-End Financial Results and Business Update Conference Call2024-03-28T15:45:00Z<![CDATA[ROSELAND, N.J., March 28, 2024 (GLOBE NEWSWIRE) -- Milestone Scientific Inc. (NYSE:MLSS), a leading developer of computerized drug delivery instruments, that provide painless and precise injections, today announced that it will host a conference call at 8:30 AM Eastern Time on Monday, April 1, 2024, to discuss the company’s financial results for 2023, as well as the company’s corporate progress and other developments]]>https://www.globenewswire.com/news-release/2024/03/28/2854174/0/en/First-Bank-Announces-First-Quarter-2024-Earnings-Conference-Call.html?f=22&fvtc=8&fvtv=New%20JerseyFirst Bank Announces First Quarter 2024 Earnings Conference Call2024-03-28T14:30:00Z<![CDATA[HAMILTON, N.J., March 28, 2024 (GLOBE NEWSWIRE) -- First Bank (Nasdaq Global Market: FRBA) invites participation in a conference call to discuss the Company’s financial and operating performance during its first quarter ended March 31, 2024.]]>https://www.globenewswire.com/news-release/2024/03/28/2854129/0/en/Lidar-Market-size-worth-5-16-Billion-Globally-by-2031-at-8-01-CAGR-Report-By-Verified-Market-Research.html?f=22&fvtc=8&fvtv=New%20JerseyLidar Market size worth $ 5.16 Billion, Globally, by 2031 at 8.01% CAGR – Report By Verified Market Research®2024-03-28T14:00:00Z<![CDATA[Revolutionize Your Perception: Dive into the Lucrative Lidar Market! Unlock Growth Opportunities, Trends, and Forecasts. Stay Ahead with Comprehensive Market Insights. Seize Your Competitive Edge Now. Revolutionize Your Perception: Dive into the Lucrative Lidar Market! Unlock Growth Opportunities, Trends, and Forecasts. Stay Ahead with Comprehensive Market Insights. Seize Your Competitive Edge Now.]]>https://www.globenewswire.com/news-release/2024/03/28/2854096/0/en/Verizon-Joins-RE100-and-Shares-New-Milestones-in-its-Responsible-Business-Plan.html?f=22&fvtc=8&fvtv=New%20JerseyVerizon Joins RE100 and Shares New Milestones in its Responsible Business Plan2024-03-28T13:30:00Z<![CDATA[NEW YORK, March 28, 2024 (GLOBE NEWSWIRE) -- Today, Verizon announced it has joined RE100, a global initiative bringing together the world’s most influential businesses committed to 100% renewable electricity. Led by the Climate Group and in partnership with CDP, RE100’s mission is to accelerate change towards zero carbon grids at scale, an objective that Verizon is proud to support. As previously announced, Verizon aims to source renewable energy equivalent to 100% of its annual electricity usage by 2030, with an interim target of 50% by 2025.]]>https://www.globenewswire.com/news-release/2024/03/28/2854057/0/en/Avalon-GloboCare-Extends-Exclusivity-Agreement-to-Distribute-KetoAir-Breathalyzer-Device-and-AI-Enabled-Software-in-North-America-South-America-United-Kingdom-and-European-Union.html?f=22&fvtc=8&fvtv=New%20JerseyAvalon GloboCare Extends Exclusivity Agreement to Distribute KetoAir Breathalyzer Device and AI-Enabled Software in North America, South America, United Kingdom and European Union2024-03-28T13:00:00Z<![CDATA[FREEHOLD, N.J., March 28, 2024 (GLOBE NEWSWIRE) -- Avalon GloboCare Corp. (“Avalon” or the “Company”) (NASDAQ: ALBT), a developer of innovative cell-based technology, cellular therapy and precision diagnostics, is pleased to announce the extension of its exclusive distribution agreement with Qi Diagnostics Limited (“Qi Diagnostics”) to distribute the KetoAir™, a breathalyzer device and related accessories, including current and future models, in key regions including North America, South America, the United Kingdom, and the European Union.]]>https://www.globenewswire.com/news-release/2024/03/28/2854005/0/en/Bannix-and-GBT-Partner-to-Bring-Revolutionary-Imaging-Tech-VisionWave-to-Market.html?f=22&fvtc=8&fvtv=New%20JerseyBannix and GBT Partner to Bring Revolutionary Imaging Tech "VisionWave" to Market2024-03-28T12:30:00Z<![CDATA[Enter into Binding Business Combination Agreement Enter into Binding Business Combination Agreement]]>https://www.globenewswire.com/news-release/2024/03/28/2853966/0/en/Agile-Therapeutics-Reports-Fourth-Quarter-Full-Year-2023-Financial-Results-and-Provides-Corporate-Update.html?f=22&fvtc=8&fvtv=New%20JerseyAgile Therapeutics Reports Fourth Quarter & Full Year 2023 Financial Results and Provides Corporate Update2024-03-28T12:05:00Z<![CDATA[Full Year 2023 Net Revenue Increased 80% from 2022 While OPEX Decreased 33%]]>https://www.globenewswire.com/news-release/2024/03/28/2853967/0/en/Tevogen-Bio-Reports-Series-A-1-Preferred-Stock-Investment-at-10-Conversion-Price.html?f=22&fvtc=8&fvtv=New%20JerseyTevogen Bio Reports Series A-1 Preferred Stock Investment at $10 Conversion Price2024-03-28T12:05:00Z<![CDATA[WARREN, N.J., March 28, 2024 (GLOBE NEWSWIRE) -- Tevogen Bio Holdings ('Tevogen Bio') (Nasdaq: TVGN), a clinical-stage specialty immunotherapy biotech pioneer developing off-the-shelf, genetically unmodified T cell therapeutics in virology, oncology, and neurology, has entered into a securities purchase agreement with an existing investor pursuant to which the investor agreed to purchase shares of newly designated Series A-1 Preferred Stock of the Company in lieu of Series A Preferred Stock that the investor earlier agreed to purchase, for an aggregate purchase price of $6.0 million.]]>